NRAS and malignant colon neoplasm: A recent study on Chinese patients showed that among KRAS, BRAF, PIK3CA and NRAS mutations in stage II to III colon cancers (n = 228), only PIK3CA mutations were an independent prognostic biomarker for poor OS among stage III patients34.